Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects
Nectin-4 is a cell adhesion molecule which has gained more and more attention as a therapeutic target in cancer recently. Overexpression of Nectin-4 has been observed in various tumors, including breast cancer, and is associated with tumor progression. Enfortumab vedotin(EV)is an antibody-drug conju...
Saved in:
| Main Authors: | Yufei Wang, Guangliang Li, Hanying Wang, Quan Qi, Xian Wang, Haiqi Lu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Breast |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977624001693 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure
by: Bożena Sikora-Kupis, et al.
Published: (2024-01-01) -
Lung Toxicity Occurring During Enfortumab Vedotin Treatment: From a Priming Case Report to a Retrospective Analysis
by: Grégoire Desimpel, et al.
Published: (2024-11-01) -
Enfortumab vedotin induced interstitial lung disease: A first case report with pathological evidence from transbronchial lung cryobiopsy
by: Shota Kaburaki, et al.
Published: (2025-01-01) -
Progress of antibody–drug conjugates in the treatment of locally advanced or metastatic urothelial carcinoma: opportunities and challenges
by: Fanhao Zeng, et al.
Published: (2025-05-01) -
Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium
by: Catherine C. Fahey, et al.
Published: (2025-05-01)